Skip to main content
Equibles
BRTX logo

BRTX · BioRestorative Therapies, Inc. · Webcasts, Transcripts & Audio

Track BRTX — free

Use BRTX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BRTX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.24 +0.10 (+4.67%)
Rebalance outlook locked
Going-concern doubt — flagged May 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“we believe we do not have sufficient cash for at least twelve months after the issuance date of the financial statements included in this Quarterly Report which raises substantial doubt about our ability to continue as a going concern.”
View the 10-Q filed May 14, 2026
Market Cap
$2.97M
Shares
1.27M
Volume · Oct 5 85.23K Avg daily vol (18 sessions) 28.81K

BioRestorative Therapies, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for BioRestorative Therapies, Inc. (BRTX), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲11.8% $35,000 −$2.22M '24 Q1 24-03-31 ▲38.1% $89,100 −$4.03M '24 Q2 24-08-06 ▲660.9% $233,600 −$1.09M '24 Q3 24-11-13 ▲124.4% $43,300 −$1.64M '24 Q4 25-03-27 ▼28.6% $25,000 −$5.34M '25 Q1 25-05-14 ▲240.4% $303,300 −$2.66M '25 Q2 25-08-12 LATEST ▼94.9% $11,800 −$3.04M '25 Q3 25-11-12
Earnings call
FY25 · Q3
2025-11-12
BioRestorative Therapies, Inc. (BRTX) Q3 2025 Earnings Call Transcript
Positive tone BRTX-100 Phase II enrollment and clinical progress Biocosmeceuticals commercial business and Cartessa FDA regulatory strategy and Fast Track designation
Revenue
$11,800
▼ 94.9% YoY
Diluted EPS
$-6.60
Gross margin
10.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-12
BioRestorative Therapies, Inc. (BRTX) Q2 2025 Earnings Call Transcript
Confident tone BRTX-100 Phase II trial enrollment and data FDA regulatory pathway and Type B meeting ThermoStem metabolic program and licensing
Revenue
$303,300
▲ 240.4% YoY
Diluted EPS
$-6.00
Gross margin
97.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-14
BioRestorative Therapies, Inc. (BRTX) Q1 2025 Earnings Call Transcript
Confident tone BRTX-100 Phase II cLDD trial ThermoStem metabolic program Clinical data and presentations
Revenue
$25,000
▼ 28.6% YoY
Diluted EPS
$-12.80
Gross margin
88.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-27
BioRestorative Therapies, Inc. (BRTX) Q4 2024 Earnings Call
Revenue
$43,300*
▲ 124.4% YoY
Gross margin
92.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-13
BioRestorative Therapies, Inc. (BRTX) Q3 2024 Earnings Call Transcript
Confident tone Efficacy endpoints (VAS, ODI, RMDQ) Indication expansion to cervical ThermoStem brown fat program
Revenue
$233,600
▲ 660.9% YoY
Diluted EPS
$-2.60
▼ 133.3% YoY
Gross margin
92.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
BioRestorative Therapies, Inc. (BRTX) Q2 2024 Earnings Call Transcript
Confident tone ThermoStem metabolic/obesity program and GLP-1 comparison Cartessa commercial agreement and BioCosmeceutical revenue BRTX-100 Phase 2 clinical study and enrollment
Revenue
$89,100
▲ 38.1% YoY
Diluted EPS
$-10.00
Gross margin
92.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-03-31
BioRestorative Therapies, Inc. (BRTX) Q1 2024 Earnings Call Transcript
Confident tone ThermoStem Metabolic Program BRTX-100 Phase 2 Clinical Trial Intellectual Property and Partnerships
Revenue
$35,000
▲ 11.8% YoY
Diluted EPS
$-6.60
Gross margin
100.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–7 of 7 webcasts
Key facts CIK 1505497 CUSIP 090655606 13F (30d) 1 filings 1 filers Visit website Investor relations